← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV28행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
oncolytic vaccinia virus (IDOV-Immune, IDOV-Immune (oncolytic vaccinia virus))
ViroMissile, Inc.·Colorectal Cancer
40 trials
Overview
Program
IDOV-Immune (oncolytic vaccinia virus)
Overview
Company
ViroMissile, Inc.
Overview
Modality
CGT
Overview
Target
Colorectal Cancer
Overview
Indication
Colorectal Cancer; Pancreatic Cancer
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Vector
viral vector platforms
MoA
Mechanism
targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway
MoA
Biomarker
PD-1-directed IL-2 expression
PK/PD
Species
Dog
PK/PD
Animal (cat.)
Dog, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Dog
Toxicology
Animal (cat.)
Dog, In vitro
Toxicology
Major finding
Oncolytic Viruses for Cancer Therapy in Dogs.. Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. T…
Clinical
Safety signal
Oncolytic Viruses for Cancer Therapy in Dogs.. Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. T…
Clinical
Selected reported efficacy
ORR 80%
Clinical
Reported ORR
80.0%
Clinical
Reported PFS
10
Clinical
Reported OS
33.6
Clinical
Result source
ClinicalTrials.gov NCT02759588
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT02759588
IDOV-Immune (oncolytic vaccinia virus) 비교 | 바이오정보모아